Liposomal Nanotechnology and its role in vaccine delivery systems
Future Medicine India|October 2021
In the recent past, there have been many projects to develop sub-unit vaccines that are more effective and defined
ARUN KEDIA
Liposomal Nanotechnology and its role in vaccine delivery systems

Vaccination or immunization is the injection of small amounts of weakened or killed bacteria and viruses, or their parts, to trigger an immune response and produce antibodies against that particular pathogen. The vaccine prepares the body to fight against the infection-causing organism when it actually enters the organism. This is classical vaccine development.

However, in more recent times, research has been focused on developing subunit vaccines that are more effective and defined. However, due to their synthetic nature, the immune response generated is weak. With the advent of COVID-19 and other complex pathogens like HIV and drug-resistant tuberculosis, there has been an increase in the challenges posed to the development of efficacious vaccines. Antigens susceptible to genetic mutations are another source of concern. In today’s population where immunity is compromised due to poor lifestyle and habits, it is all the more challenging to develop vaccines that deliver best results.

In this complex and trying time, Liposomal Nanotechnology has been gaining a lot of attention, especially in the field of vaccine development. It has been the subject of research ever since 1960, and has since then proven to be a profound, robust and stable novel drug delivery platform. The new, mRNA-based Covid 19 vaccine is a proven and strong example of a liposomal-based drug delivery system (lipid nanotechnology) being used to reach target cellular sites.

Liposomes - Superior Drug Delivery Platforms

Diese Geschichte stammt aus der October 2021-Ausgabe von Future Medicine India.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der October 2021-Ausgabe von Future Medicine India.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS FUTURE MEDICINE INDIAAlle anzeigen
Early Reports On Omicron Encouraging: Anthony Fauci
Future Medicine India

Early Reports On Omicron Encouraging: Anthony Fauci

Even as the Omicron variant of coronavirus is spreading across the world quickly, early reports suggest that it may cause less severe disease than the Delta variant, says Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, US.

time-read
8 Minuten  |
December 2021
Air Pollution Reduces 8 Years Of Life Expectancy In India
Future Medicine India

Air Pollution Reduces 8 Years Of Life Expectancy In India

India registers 18 percent of deaths annually due to air pollution and related diseases, while nationwide socioeconomic inequalities persist in asthma diagnosis across India

time-read
10+ Minuten  |
December 2021
Future Medicine India

Importance Of Adhering To Covid Appropriate Behaviour

As the efficacy of existing vaccines has been proven to be inadequate against Omicron, our only hope from the jab is to reduce the severity of the disease, highlighting the importance of adhering to covid appropriate behaviour

time-read
10+ Minuten  |
December 2021
AstraZeneca's new covid drug AZD7442 shows 83% prevention and 88% treatment efficacy
Future Medicine India

AstraZeneca's new covid drug AZD7442 shows 83% prevention and 88% treatment efficacy

AstraZeneca, which announced the latest data from Phase III trials of its new Covid-19 drug -- AZD7442 -- said both the prevention and outpatient treatment studies showed robust efficacy from a onetime intramuscular (IM) dose of the long-acting antibody combination.

time-read
1 min  |
December 2021
VACCINES IN YOUR POCKET
Future Medicine India

VACCINES IN YOUR POCKET

DR. SAUMYA SWAMINATHAN Cheif Scientist, World Health Organisation

time-read
1 min  |
December 2021
DIABETES, AT CLOSE TO 91 MILLION CASES, ACCOUNTS FOR 25% OF ALL NCDS IN INDIA
Future Medicine India

DIABETES, AT CLOSE TO 91 MILLION CASES, ACCOUNTS FOR 25% OF ALL NCDS IN INDIA

The disease incidence, which increases very rapidly in individuals above 35 years of age, accounts for 12.8 million DALYs, 6.7 million YLDs

time-read
4 Minuten  |
December 2021
EXPERTS PREDICT THIRD WAVE IN INDIA WITH MORE THAN A LAKH DAILY CASES IN FEBRUARY
Future Medicine India

EXPERTS PREDICT THIRD WAVE IN INDIA WITH MORE THAN A LAKH DAILY CASES IN FEBRUARY

The active cases have come down as compared July leveld, the threat of new variants is looming large.

time-read
1 min  |
December 2021
END INEQUALITIES TO MEET THE TARGET OF ENDING AIDS
Future Medicine India

END INEQUALITIES TO MEET THE TARGET OF ENDING AIDS

Forty years after the first AIDS case was reported, and 35 years since the first case in India, HIV still threatens us. Today, the world is off track from delivering on the shared commitment to end AIDS by 2030.

time-read
4 Minuten  |
December 2021
CONVENTIONAL LINEN IS ONE OF THE BIGGEST CULPRITS IN HOSPITAL ACQUIRED AS WELL AS SURGICAL SITE INFECTIONS
Future Medicine India

CONVENTIONAL LINEN IS ONE OF THE BIGGEST CULPRITS IN HOSPITAL ACQUIRED AS WELL AS SURGICAL SITE INFECTIONS

The ‘green colour’ linen is synonymous with hospitals, as it has been in use for centuries in hospitals world over, especially the conventional healthcare settings. But how many, even in the medical community, are really conscious about the responsibility for and the critical role of this piece of medical accessory in ensuring patient safety? Evidence from most hospitals in India indicates that not many are aware of the standards, and even if they are, not many bother with them. Again, going by real world experience, there exists another paradox. Though the actual cost of the repeated use of the linen is higher than the cost of single-use disposables (recommended in modernday care), it is still being used in a large majority of hospitals and clinics in India — because it is the convention. Therefore, transformation hesitance is more of a mindset issue rather than ignorance or economics. Most in the industry also oppose quality regulations in the country. In a market where hundreds of textile weavers and cloth merchants turned medical mask and accessory manufacturers overnight during the Covid pandemic, the market situation serves the unscrupulous minds who only eye the profits. However, there are a handful of local companies, besides the large organised players, who stick to quality products in this predominently price conscious market due to internal SOPs or pure commitment. For JAMES GEORGE, Founder and Managing Director at Kochi-based Careon Healthcare Solutions, it is more of a personal commitment. In a freewheeling interview with Editor CH UNNIKRISHNAN, George says that the primary reason behind the rise of unscrupulous players in the medical disposables market is lack of awareness among the users and the patients. Edited excerpts:

time-read
5 Minuten  |
December 2021
UK approves sotrovimab as new covid treatment for high risk adults
Future Medicine India

UK approves sotrovimab as new covid treatment for high risk adults

The Medicines and Healthcare Products Regulatory Agency (MHRA), the drug regulator of the UK, has approved sotrovimab, branded as Xevudy, a new biological drug to fight Covid-19. The drug was found effective to reduce the likelihood of hospital admission and death by about 79 percent in high-risk adults.

time-read
3 Minuten  |
December 2021